Why You Should Be Careful About 23andMe’s Health Test
By The Editorial Board,
The New York Times
| 02. 01. 2019
Last month, the DNA-testing company 23andMe secured Food and Drug Administration approval for a new screening for gene-based health risks. Along with celiac disease, Alzheimer’s, Parkinson’s, breast cancer and several other medical conditions, the company can now screen clients for two mutations that have been linked to colorectal cancer.
But “F.D.A.-approved” does not necessarily mean “clinically useful.” 23andMe relies on much simpler technology than tests that you’d get at your doctor’s office. As a result, the company’s tests cannot tell you much about your actual risk of developing the diseases in question.
Here’s how those tests work — and why you should interpret them with caution.
They read your gene.
You can think of your genes as long text documents. The words are your genetic code. Genetic mutations are like typos — imperfections that scientists can spot with some scrutiny.
They compare your gene against a reference gene to find problems.
DNA tests are scientists’ way of proofreading your genes — which they accomplish by comparing them against a gene that’s considered healthy.
23andMe’s test reviews a handful of locations
...
Related Articles
By Anumita Kaur [cites CGS’ Katie Hasson], The Washington Post | 03.25.2025
Genetic information company 23andMe has said that it is headed to bankruptcy court, raising questions for what happens to the DNA shared by millions of people with the company via saliva test kits.
Sunday’s announcement clears the way for a new...
By Peter Wehling, Tino Plümecke, and Isabelle Bartram
| 03.26.2025
This article was originally published as “Soziogenomik und polygene Scores” in issue 272 (February 2025) of the German-language journal Gen-ethischer Informationsdienst (GID); translated by the authors.
In mid-November 2024, the British organization Hope not Hate published its investigative research ‘Inside the Eugenics Revival’. In addition to documentating an active international “race research” network, the investigation also brought to light the existence of a US start-up that offers eugenic embryo selection. Heliospect Genomics aims to enable wealthy couples to...
By Frank Landymore, Futurism | 03.18.2025
You can only throw so much money at a problem.
This, more or less, is the line being taken by AI researchers in a recent survey. Asked whether "scaling up" current AI approaches could lead to achieving artificial general...
By Craig S. Smith, Forbes | 03.08.2025
One recent evening in Shenzhen, a group of software engineers gathered in a dimly lit co-working space, furiously typing as they monitored the performance of a new AI system. The air was electric, thick with the hum of servers and...
